Red Bear Angels portfolio company Biotia has raised an oversubscribed $9 million financing to scale its New York City laboratory, expand its diagnostic menu in women's health, and enter orthopedic diagnostics. The financing exceeds the company's previously announced Series A.
Alongside the financing, Biotia expanded its board and advisory team with healthcare leaders including Michele Colucci as board chair, Tim Barry as a board member, and Clive Fields as a board observer. Additional advisors bring expertise in women's health diagnostics, clinical operations, commercialization, and healthcare innovation.
Biotia's BIOTIA-ID Urine Test identifies the cause of recurrent and complicated urinary tract infections with 97% sensitivity and 99% specificity and is available to physicians and patients in all 50 states. The company is using the new capital to pursue reimbursement and make advanced infectious disease diagnostics more accessible.
